Datasets
Buyer room
VAMSTAR.IOManage supplier listing
Vamstar — Cross-market pharmaceutical NET price and discount benchmark panel: estimated net (post-discount) drug prices and gross-to-net spreads at therapy level across 40+ developed and emerging markets, on a uniform cross-market methodology, with event annotations for new launches, significant price adjustments, volume shifts and patient-support programme changes, plus a monthly analyst narrative layer explaining the drivers behind net price movements.. Mid-size specialist: 82 employees, ~EUR 9.5M raised, ~EUR 4.9M revenue, London-based, selling an analyst-supported subscription panel acros…
supplier index read from their site
Cross-market pharmaceutical NET price and discount benchmark panel: estimated net (post-discount) drug prices and gross-to-net spreads at therapy level across 40+ developed and emerging markets, on a uniform cross-market methodology, with event annotations for new launches, significant price adjustments, volume shifts and patient-support programme changes, plus a monthly analyst narrative layer explaining the drivers behind net price movements.
From 6 yearsCoverage Health CareAsset class Equities
Sample, licence terms, pricing and eval results when Vamstar publishes them. Until then, discover alternatives today with a 7-day trial.
Start 7-day trial →What buyers ask about Vamstar, answered from this page.
Vamstar — Cross-market pharmaceutical NET price and discount benchmark panel: estimated net (post-discount) drug prices and gross-to-net spreads at therapy level across 40+ developed and emerging markets, on a uniform cross-market methodology, with event annotations for new launches, significant price adjustments, volume shifts and patient-support programme changes, plus a monthly analyst narrative layer explaining the drivers behind net price movements.. Mid-size specialist: 82 employees, ~EUR 9.5M raised, ~EUR 4.9M revenue, London-based, selling an analyst-supported subscription panel acros…
Vamstar offers (Alternative, Fundamental, Reference) — Order of 10^5-10^6 therapy-market-period net price observations (40+ markets x several hundred therapy areas x monthly/quarterly periods since launch), plus a comparable count of annotated change events and driver attributions.
Gross-to-net benchmarking and contract/rebate benchmarking (explicitly named); training tabular models that predict net price erosion and discount intensity by therapy and market; validating market-access and pricing engines; scenario modelling for US MFN / price-transparency policy shocks; constructing ground-truth labels for price-change event detection in pharma text/news models
The data is with 6 years of history.
Coverage spans US, UK, Europe, Japan; Pharmaceuticals; alternative, fundamental, reference; equities.
Vamstar has not added their own details yet. Not yet on file: